You are here: Industry Insights > Rebiotix

News List

Rebiotix, Ferring's microbiome-based therapy RBX2660 shows promise pharmatimes
May 07, 2020
Rebiotix and Ferring Pharmaceuticals have unveiled positive preliminary findings from an ongoing pivotal late-stage trial of the investigational microbiome-based treatment RBX2660.
Ferring, Rebiotix and Karolinska Institutet Extend Collaboration to Research Next Generation of Microbiome Treatments pharmafocusasia
January 24, 2019
Ferring Pharmaceuticals and Karolinska Institutet announced today a five-year extension of their collaboration to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology....
Ferring Acquires Rebiotix americanpharmaceuticalreview
April 09, 2018
Ferring Pharmaceuticals and Rebiotix announce they have agreed to the acquisition of Rebiotix by Ferring.
Ferring acquires Rebiotix Inc. biospectrumasia
April 08, 2018
The most advanced investigational microbiome treatment from Rebiotix is RBX2660, a non-antibiotic treatment currently in Phase 3 development for the prevention of recurrent CDI
Ferring Buys Rebiotix: Acquires Phase III Non-Antibiotic Treatment biospace
April 08, 2018
Ferring Pharmaceuticals, headquartered in Saint-Prex, Swizerland, is acquiring Roseville, Minnesota’s Rebiotix. Financial details have not been disclosed.
Rebiotix Announces First Patient Enrolled in RBX2660 Phase 3 Clinical Trial americanpharmaceuticalreview
August 08, 2017
Rebiotix has enrolled the first patient in a Phase 3 clinical trial of RBX2660 for the prevention of recurrent Clostridium difficile (C. diff) infection.RBX2660 is the first drug product in clinical study from the Microbiota Restoration Therapy (MRT) plat
Rebiotix delivers a gut bug PUNCH in C. diff trial pharmafile
April 14, 2017
Rebiotix is one a new breed of companies that aims to use the human body’s microbiome to treat illnesses and conditions ...